Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of switching to tenofovir alafenamide (TAF) avoid organ toxicity associated with other anti-hepatitis B virus (HBV) medications in chronic HBV positive patients

Trial Profile

Study of switching to tenofovir alafenamide (TAF) avoid organ toxicity associated with other anti-hepatitis B virus (HBV) medications in chronic HBV positive patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2018 New trial record
    • 10 Oct 2018 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top